496 related articles for article (PubMed ID: 28742703)
1. Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy: The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy.
Habr-Gama A; São Julião GP; Vailati BB; Sabbaga J; Aguilar PB; Fernandez LM; Araújo SEA; Perez RO
Ann Surg; 2019 Jan; 269(1):102-107. PubMed ID: 28742703
[TBL] [Abstract][Full Text] [Related]
2. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
[TBL] [Abstract][Full Text] [Related]
3. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
4. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen.
Habr-Gama A; Perez RO; São Julião GP; Proscurshim I; Fernandez LM; Figueiredo MN; Gama-Rodrigues J; Buchpiguel CA
Radiat Oncol; 2016 Feb; 11():24. PubMed ID: 26911200
[TBL] [Abstract][Full Text] [Related]
5. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
Habr-Gama A; Sabbaga J; Gama-Rodrigues J; São Julião GP; Proscurshim I; Bailão Aguilar P; Nadalin W; Perez RO
Dis Colon Rectum; 2013 Oct; 56(10):1109-17. PubMed ID: 24022527
[TBL] [Abstract][Full Text] [Related]
6. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Habr-Gama A; Gama-Rodrigues J; São Julião GP; Proscurshim I; Sabbagh C; Lynn PB; Perez RO
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):822-8. PubMed ID: 24495589
[TBL] [Abstract][Full Text] [Related]
7. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
[TBL] [Abstract][Full Text] [Related]
8. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
9. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
[No Abstract] [Full Text] [Related]
10. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
[TBL] [Abstract][Full Text] [Related]
11. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
12. Transanal local excision for distal rectal cancer and incomplete response to neoadjuvant chemoradiation - does baseline staging matter?
Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Coelho AQ; Figueiredo MN; Fernandez LM; Gama-Rodrigues J
Dis Colon Rectum; 2014 Nov; 57(11):1253-9. PubMed ID: 25285691
[TBL] [Abstract][Full Text] [Related]
13. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.
Martens MH; Maas M; Heijnen LA; Lambregts DM; Leijtens JW; Stassen LP; Breukink SO; Hoff C; Belgers EJ; Melenhorst J; Jansen R; Buijsen J; Hoofwijk TG; Beets-Tan RG; Beets GL
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27509881
[TBL] [Abstract][Full Text] [Related]
15. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study.
Gérard JP; Barbet N; Gal J; Dejean C; Evesque L; Doyen J; Coquard R; Gugenheim J; Benizri E; Schiappa R; Baudin G; Benezery K; François E
Eur J Cancer; 2019 Feb; 108():1-16. PubMed ID: 30580125
[TBL] [Abstract][Full Text] [Related]
16. Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
Habr-Gama A; Lynn PB; Jorge JM; São Julião GP; Proscurshim I; Gama-Rodrigues J; Fernandez LM; Perez RO
Dis Colon Rectum; 2016 Apr; 59(4):264-9. PubMed ID: 26953984
[TBL] [Abstract][Full Text] [Related]
17. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.
Creavin B; Ryan E; Martin ST; Hanly A; O'Connell PR; Sheahan K; Winter DC
Br J Cancer; 2017 Jan; 116(2):169-174. PubMed ID: 27997526
[TBL] [Abstract][Full Text] [Related]
18. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
19. Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years.
Strode M; Shah R; Boland PM; Francescutti VA; Mangieri CW; Attwood K; Nurkin SJ
Surg Oncol; 2019 Mar; 28():116-120. PubMed ID: 30851884
[TBL] [Abstract][Full Text] [Related]
20. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
